Introduction
Besides poxvirus-based vectors, whose suitability for in vivo expression of foreign genes is now well demonstrated, several other virus families (Adenoviridae, Herpesviridae, etc.) are candidates for use as viral vectors in the vaccination of animals. Among these viruses, the potential use of adenovirus type 5 (Ad5) as a gene transfer vector is based on different arguments: its genetic organization has been widely studied; different deletion mutants with insertion capacities of up to 7 kbp have been isolated and can be propagated in Ad-transformed human cell lines, for example 293 ceils (for review see Berkner, 1988) ; the high copy number of the genome in infected cells and the strength of some viral promoters lead to the synthesis of large amounts of viral products during replication; Ad5 seems to have a wide host range and has been shown to replicate in man, rabbits (Ballay et al., 1985 (Ballay et al., , 1987 , hamsters (Morin et al., 1987) , mice (Johnson et al., 1988) and pigs (Betts et al., 1962) . Recombinant Ad5 harbouring the hepatitis B surface antigen (HBsAg) gene were capable of inducing antibodies against HBsAg in rabbits (Ballay et al., 1985 (Ballay et al., , 1987 and in chimpanzees (Levrero et al., 1987) . To test the suitability of Ad5 as an in vivo gene transfer vector in several animal species, it appeared necessary to use a model which could permit easy and fast virulent challenges in a wide range of host species. Pseudorabies virus (PRV) was chosen because of this and its economic importance in the swine industry.
Among the different glycoproteins of PRV, gp50 seems to be a good candidate for a subunit vaccine. Wathen et al. (1985) first demonstrated that gp50 was a target of neutralizing monoclonal antibodies which can protect mice against a PRV challenge. We recently extended these findings by showing that gp50 is the only protein recognized by neutralizing monoclonal antibodies derived from a fusion using spleen cells from a mouse inoculated with live virus as immunogen (Eloit et al., 1988) . Furthermore gp50 delivered either to mice via infection by a recombinant vaccinia virus, or to pigs as a protein produced in CHO cells was shown to protect against PRV-induced disease (Marchioli et al., 1987) .
We describe in this report the construction of a recombinant adenovirus which harbours the open reading frame coding for gp50 (Petrovskis et al., 1986) under the control of the major late promoter of adenovirus. The recombinant virus expresses high levels of gp50 in cell lines which either complement or do not complement the defective E1 function of the Ad5. Injected into rabbits and mice, this recombinant virus elicits the production of antibodies against gp50 and can protect animals from virulent challenge with PRV.
Methods
Cells and virus. Cell line 293, an adenovirus-transformed human embryonal cell line (Graham et al., 1977) , was used for DNA transfection and adenovirus multiplication and titration. These cells were maintained in Dulbecco's modified Eagle's medium containing 10% foetal calf serum (FCS). Construction of Ad-gp50 used a human Ad5 deleted in the E3 region (Ad~d1327) which is not essential to the growth of the virus in vitro or in vivo (Shenk & Williams, 1984) . Pseudorabies virus (Kojnok strain) was grown on pig kidney cells (PK15) and titrated on Vero cells, both maintained in Eagle's minimum essential medium with 10~ FCS. HeLa cells were cultivated in the same medium.
Plasmids. The plasmid pPRVB7 which contains the BamHI fragment 7 of the NIA3 PRV strain, cloned at the unique BamHI site of pBR322, was a gift from Gila Kohen (Rh6ne-M6rieux, Lyon, France). The eukaryotic expression vector pMLPI 0 has already been described (Ballay et aL, 1987) . This plasmid contains the extreme left end of the Ad5 genome with the major late promoter (MLP) of Ad2 joined to its tripartite leader sequence, pMLPIOCAT was a gift from Dominique Brechemier Baey (Institut Gustave Roussy, Villejuif, France). It contains the chloramphenicol acetyltransferase (CAT) gene followed by splicing (nucleotides 4705 to 4099) and polyadenylation (nucleotides 2770 to 2553) signals from simian virus 40 (SV40), cloned downstream from the MLP and its tripartite leader sequence.
Transfection and isolation of recombinant virus. Recombinant viral DNA obtained by in vitro ligation of heterologous fragments (see results) was transfected into 293 cells using calcium phosphate precipitation (Graham & Van der Eb, 1973) . Plaques were isolated 10 days later and expanded. Viral DNA was extracted by the Hirt procedure (Graham et al., 1977) and recombinant viruses were identified by restriction analysis.
Identification and quantification of gp50
(i) Western blot. Adenovirus-infected cells were lysed 3 days postinfection (p.i.) in 0-05 M-Tris-HCI pH 8, 0.5 M-NaC1, 1 ~ Triton X-100, 0.1~ deoxycholate. Solubilized proteins were fractionated by SDS-PAGE in non-reducing conditions, then transferred to nitrocellulose sheets as described (EMit et al., 1988) . The gp50 was probed by a monoclonai antibody (10X 16) (Eloit et al., 1988) and the reaction was developed using anti-mouse IgG antibodies conjugated to alkaline phosphatase (Promega Biotech).
(ii) ELISA. An ELISA was used to measure levels of expression of gp50 in adenovirus-infected cells. Adherent cells and cells floating in the medium, collected by centrifugation, were pooled and lysed as above. Serial dilutions (100 ktl) of cell extracts to be tested were used to coat microplate wells and the presence of gp50 was revealed by using the 10X16 monoclonal antibody. Bound antibodies were identified by biotin-labelled anti-mouse antibodies (Amersham). The subsequent steps of the reaction have already been described (Eloit et al., 1989) . The ELISA titre of cell extracts was considered to be the last dilution giving a signal higher than that of the negative control (Ad-d1327-infected cell extract). Conversion of ELISA titres to gp50 concentrations was made by using a cell extract with a known concentration of gp50 as a reference. This standard had been titrated in radial immunodiffusion with affinity chromatography-purified gp50 as a reference (Chappuis et al., 1989) .
Detection of antibodies against gp50
(i) ELISA. PRV envelope proteins of purified virus were solubilized as described (Eloit et aL, 1989) and used to coat wells of microplates. Serial dilutions of sera from inoculated animals were made in phosphate-buffered saiine (PBS) pH7-2, 0-05~ Tween 20 and incubated for I h at 37 °C. Revelation of bound antibodies from rabbits or mice was done, respectively, with biotin-labelled Protein A or with biotin-labelled anti-mosue IgG antibodies and streptadivin-peroxidase (Amersham). Serum titres were expressed as the last dilution giving an absorbance reading greater than 0.150.
(ii) Neutralization assay. Serial dilutions of sera were mixed with 100 p.f.u, of PRV, incubated for 1 h at 37 °C, then plated on Vero cells. After 1 h at 37 °C, cells were overlaid with agar. Plaques were counted 3 days later. Serum titres were expressed as the dilution required to neutralize 50% of the input virus.
Inoculation of animals with recombinant adenovirus and viral challenge with PR V. New Zealand rabbits and BALB/c mice were inoculated by different routes with recombinant adenovirus or Ad-d1327 as a negative control. Adenoviruses to be inoculated were first purified by banding twice in CsCI density gradients to avoid carrying gp50 from cell culture and were extensively dialysed against PBS before inoculation. Viral challenge involved intramuscular injection of 102 or 104 p.f.u, respectively of PRV (Kojnok strain) into rabbits and mice. These doses represent at least 30 LDso for the corresponding species. The clinical status of each animal was monitored daily for a 1 month period after challenge.
Results

Construction of the recombinant adenovirus Ad-gp50
An adenovirus containing the PRV gp50 gene under the control of the Ad2 MLP was constructed as described in Fig. 1 . The NdeI-StuI fragment of pPRVB7 was cloned between the NdeI and HindlII sites of PBR322, after filling in the HindlII end with Klenow polymerase, to give plasmid pPRVSN. This was done in order to eliminate some undesirable NarI sites upstream and downstream of the gp50 gene. The construction of the expression vector used the NarI site 36 bp upstream of the translation initiation signal and the MaelII site 47 bp downstream of the translation stop signal. Partial NarI digestion and MaelII digestion of pPRVSN gave a 1287 bp fragment containing the whole coding sequence of gp50. After filling in the MaelII end with Klenow polymerase, this fragment was inserted between the ClaI and HpaI sites of pMLPIOCAT to give pMLPIOGP50.5, in which the SV40 polyadenylation signal follows the gp50 coding sequence without any splicing signals. A ClaI site, necessary for the construction of the recombinant adenovirus, was created by ,digesting the unique BamHI site of pMLP10GP50.5, :filling in the ends with Klenow polymerase and, religating to give pMLP10GP50.6. The ability of pMLP10GP50.6 to direct the synthesis of high levels of igp50 was demonstrated in a transient expression assay ~after transfection of 293 cells and immunoprecipitation ~f cell lysates by anti-gp50 monoclonal antibodies I(results not shown).
To construct the recombinant virus, the plasmid pMLP10GP50.6 was digested with PstI and ClaI. The fragment which contains the gp50 gene was used to replace the extreme left end of Ad-d1327 by ligation at the unique ClaI site. After ligation, the DNA was transfected into 293 cells and, 10 days later, plaques were picked and viral DNAs were tested by restriction analysis. A positive clone (Ad-gp50) was retained for subsequent analyses. Ballay et al., 1985) ; pA, polyadenylation signal of the SV40 A gene (nucleotides 2770 to 2553); In, splicing signals of SV40 (nucleotides 4705 to 4099). (b) Ad-gp50 was constructed after ligation of the purified large Clal fragment of Ad-d1327 (2.6 to 100 map units) with the PstI-Ctal fragment of pMLP10GP50.6. After ligation the DNA was transfected into 293 cells and plaques were picked 10 days later. Black box, nucleotides 1 to 455 of the AdS genome followed by the MLP and its tripartite leader sequence; hatched box, gp50 coding sequence and polyadenylation signal of SV40.
Expression of the gp50 glycoprotein by Ad-gp50 in cell culture
The capacity of Ad-gp50 to direct gp50 expression was tested in cells either complementing the E 1 function (293 (Fig. 2) . Two bands with variations in M, depending on the host cell were sometimes detected (Fig. 2, lanes 2 and 4) . This pattern has already been described for proteins from PRV-infected cells immunoprecipitated by an anti-gp50 monoclonal antibody (Kost et al., 1989) . The lower band seems to be a non-glycosylated precursor of the mature glycoprotein (Petrovskis et al., 1986) . Although high levels of gp50 expression could be detected by Western blotting in 293 (lane 2) and HeLa (lane 4) infected cells, Vero cells showed only small amounts of gp50 (lane 6).
The level of gp50 expression seemed to be related to the extent of replication of the virus. This result was not unexpected, but it was more surprising to note that levels of expression of gp50 in HeLa cells were higher than in 293 cells even though HeLa cells do not supply the E1 . Infected cells were collected at different times after infection. Cell extracts were studied with an ELISA using a reference curve derived from a standard cell extract containing a known concentration of gp50. Blood samples were taken at the date of challenge. Sera from mice were pooled before testing. § Rabbit D was not challenged with PRV but its blood was sampled 5 weeks after inoculation with Ad-gp50.
II Number of deaths/number of mice challenged.
function. Because the rate and extent of replication of Ad-gp50 were different in the three cell lines, subsequent experiments were done to quantify more precisely the level of gp50 expression at different times p.i.
Effect of E1A complementation on the kinetics and level of expression of gp50
As a main objective of the construction of Ad-gp50 was to test the potency of recombinant adenoviruses as live vaccines, it appeared necessary to quantify accurately the level of expression of gp50 in cells that could not complement the E1 gene deletion of the recombinant virus. Petri dishes containing a known number of 293, HeLa or Vero cells were infected with Ad-gp50 at an m.o.i, of 1, 10 or 100 p.f.u./cell. At different times p.i., cells were lsyed and successive dilutions of the extracts were tested with an ELISA. Glycoprotein gp50 concentrations were calculated by comparison with a reference curve derived from a standard cell extract containing a known concentration of gp50. Cumulative amounts of gp50 expressed by 106 infected cells are shown in Fig. 3 . Kinetics of antibody response of rabbits inoculated with Ad-gp50. Rabbits were inoculated with Ad-gp50 or Ad-d1327 at day 0 and at day 21 (x axis). Sera were studied with an ELISA using purified envelope proteins as antigen. ELISA titres were expressed as the last dilutions that gave an absorbance >0.150 (y axis). Details of the immunization schemes are given in Table 2 accumulation of gp50 in HeLa cells led to levels of expression which were higher than in 293 cells. On the other hand, levels of expression of gp50 were comparatively low in Vero cells. Thus, it appeared that, at least in some kinds of cells other than 293, Ad gp50 was able to induce a high level of expression of gp50. Efficient transportation of gp50 to the surface of Ad-gp50-infected 293 cells was also verified with immunofluorescence (not shown). These results were considered to be promising for using Ad-gp50 to express gp50 in animals.
Antibody response and protection from challenge with PR V in rabbits and mice vaccinated with Ad-gp50
Antibody response against gp50 was monitored in rabbits and mice after one or several injections of Ad-gp50. Immunization schemes are summarized in Table 2 . Some of the results obtained from rabbits are shown in Fig. 3 . After intravenous (i.v.), intranasal (i.n.) or intramuscular (i.m.) inoculation of a single dose of Ad-gp50, anti-gp50 antibodies were detectable 2 weeks later in all but one rabbit (rabbit F). After a second injection, a boost effect was detected in the rabbits and all rabbits showed a strong antibody response 1 week later. Analysis of the serum of rabbit F with a Western blot proved that the detected antibodies were directed against gp50 (not shown). Strong antibody responses were also detected in all groups of mice except in group 1 (Table 2 ). This result is probably due to the short interval of 1 week between the inoculation of Ad-gp50 and blood sampling.
Rabbits and mice were challenged with high doses of virulent PRV strain Kojnok (i.e. at least 30 LDso ) by the i.m. route. Results are shown in Table 2 . All the controls inoculated with Ad-d1327 died 3 to 5 days after the challenge. Only three rabbits of eight vaccinated with Ad-gp50 survived. Before challenge, these three rabbits exhibited high levels of anti-gp50 antibodies. Similar results were obtained in mice, where only a few animals survived. These surviving animals originated from groups 3 and 4, in which high levels of anti-gp50 antibodies were detected before challenge. Thus these results shows that, under the conditions of challenge used, protection against PRV challenge could only be obtained in rabbits and mice that exhibited high titres of anti-gp50 antibodies.
Discussion
The usefulness of recombinant vaccinia virus to vaccinate humans and animals against infectious diseases has been widely demonstrated (for a review, see Murphy, 1989) . Nevertheless, some drawbacks to the extensive use of such recombinant viruses still exist. One of the major disadvantages to using vaccinia recombinant viruses in animals is its wide host range, including humans, leading to the potential hazard of contamination of human populations with unknown health consequences. Using poxviruses whose replication is restricted to a few animal species is one of the possible ways to limit this risk, but virus transmission between susceptible animals remains to be studied. We have chosen to study another way of expression of foreign genes in animals, based on the use of E1A-defective human adenoviruses. The E1A gene products are major transcriptional activators, and so E1A-defective viruses replicate only poorly in cells other than 293, which is a transformed cell line encoding the E1 products of Ad5 (for reviews, see Grand, 1987; Nevins, 1987) . Therefore, it can be anticipated that viral replication in vivo, as well as the level of excretion from inoculated animals, is limited.
For the construction of Ad-gp50, the gp50 coding region was placed under the control of the major late promoter of Ad2, followed by most of its tripartite leader sequence (Berget et al., 1977) . Indeed, mRNAs containing the tripartite leader have been shown to be translated in late infected cells at least 20-fold more efficiently than mRNAs containing only the first leader (Thummel et aL, 1983) . Another main feature of the construction is the insertion of the foreign sequence at the extreme left end of the adenovirus genome, using the unique ClaI restriction site of Ad-d1327 DNA at 2-6 map units (m.u.), and thus retaining the plX sequences required for packaging full-length genomes (Ghosh-Choudhury et al., 1987) . Recent descriptions of recombinant adenoviruses engineered for in vivo expression of foreign genes used a cloning site in the E3 region without deletion of the E1 gene (Johnson et al., 1988; Lubeck et al., 1989; Schneider et al., 1989) . Johnson et al. (1988) were unable to detect herpes simplex virus (HSV) gB-related transcripts initiated from the SV40 early promoter linked to the gB coding sequence and inserted in the left to right orientation. Instead, gB-related transcripts were initiated from one or several promoters upstream in the Ad5 genome and involved multiple splicing events. Similar observations were made by Schneider et al. (1989) after cloning the glycoprotein gene from vesicular stomatitis virus linked to the HSV thymidine kinase promoter in the E3 region. Cloning in the opposite orientation (i.e. right to left) led in these two cases to a low level of expression of the inserted gene, and control of transcription by the foreign promoter was not demonstrated. Mapping of the gp50-related transcripts in Ad-gp50-infected cells was not done, but, as no promoter sequences exist upstream from the foreign MLP in the linear Ad5 genome, a contribution of Ad5 promoters to the transcription of the gp50 gene is unlikely.
We have demonstrated high levels of expression of gp50 in 293 and HeLa cells infected with Ad-gp50. Thus, it appears that gp50 expression was not strictly restricted to cells complementing the defective E1 region of the recombinant virus. These results are different from those published by Johnson et al. (1988) , who were unable to detect expression of HSV gB in HeLa cells early (24 h) after infection with 500 p.f.u./cell of an EIA defective recombinant Ad5. They detected only low levels of gB expression in a human osteosarcoma cell line late (60 h) after infection with 20 p.f.u./cell of the recombinant virus. This difference could be explained by the use of a strong promoter (MLP) with the E1A enhancer in Ad-gp50 instead of the SV40 early promoter, and by longer incubation times. In the experimental conditions used, expression of gp50 in HeLa cells was much higher than in 293 cells. A higher level of expression in HeLa cells than in 293 cells has also been reported for the same kind of construction of a recombinant adenovirus expressing the human alpha 1-antitrypsin gene product, a secreted protein (P. Gilardi, unpublished results). Finally Ad-gp50-infected Vero cells expressed low quantities of gp50, whereas a recombinant adenovirus harbouring the HbsAg gene at the same cloning site as Ad-gp50 was shown to express higher levels of HbsAg in Vero cells than in 293 cells (Ballay et al., 1987) . Taken together, these results show that, in some cell lines other than 293, high levels of expression can be induced by E1A defective recombinant adenoviruses. This observation can be explained, at least partially, by the rapid death of infected 293 cells leading to the arrest of gp50 synthesis, whereas in some other cell lines, a progressive accumulation of gp50 could compensate for the lack of trans-activation by the E1A gene. Furthermore, in cells which are not permissive for viral replication, one would expect a basal level of expression of gp50, because the transfection of the plasmid pMLP10GP50.6 leads to a high level of expression of gp50 in transfected cells (not shown).
We have shown that Ad-gp50-inoculated mice and rabbits developed a good antibody response against gp50. These results confirm previous ones obtained in rabbits with an HBsAg, recombinant Ad5 defective for EIA (Ballay et al., 1987) . Antibody responses against immunogens have also been reported in mice after inoculation of recombinant Ad5 without any deletion in the El region (Dermott et al., 1989; Prevec et al., 1989) . Thus, while mouse cells are considered semi-permissive for Ad5 replication , and in spite of the E1A deletion in Ad-gp50, the levels of gp50 produced in mice were high enough to stimulate an antibody response. This result was not unexpected in view of the demonstration of the synthesis of gp50 in HeLa and Vero cells which could also be considered semi-permissive for the replication of E1A-defective Ad5.
It was surprising that, in spite of good antibody responses, protection of Ad-gp50-inoculated mice and rabbits was not very efficient. These results can be explained either by the animal models used, or by the method used for PRV challenge. It is known that rabbits frequently give poorly reproducible results when used for the control of inactivated PRV vaccines, in spite of high levels of neutralizing antibodies induced by such vaccines (P. Vannier, personal communication) . This is probably related to the high sensitivity to PRV of rabbits, which can be killed by a single p.f.u, of virus. The protective activities of PRV live virus vaccines in rabbits are not known (because of their frequent lethality in this species), thus they cannot be compared to that of Ad-gp50. The protection of mice described in this paper can be compared with other trials using pure gp50 or a recombinant vaccinia virus harbouring the gp50 gene. Marchioli et al. (1987) reported that a recombinant vaccinia virus with the gp50 gene efficiently protected mice from a PRV challenge. Nevertheless, the conditions of challenge which were used seem to be less severe than ours, because only 80~ of the control mice died. To protect all mice against the same conditions of challenge as ours, Ishii et al. (1988) needed to inject mice twice with 5 ~tg of purified gp50 emulsified in complete Freund's adjuvant. When two doses of 1 ~tg in adjuvant were used, protection of mice was comparable to that described here for group 3.
In this report, we have shown that a recombinant Ad5 deleted in the E1 region was very efficient for in vitro expression of foreign gene products and could induce a good antibody response and protection from virulent challenge in certain animal species. This kind of result has been previously demonstrated only for non-defective recombinant AdS which used a cloning site in the E3 region (Dermott et al., 1989; Morin et al., 1987; . We anticipate that cloning in the El region may have advantages, such as lowering levels of replication in vivo and thus limiting the risks of dissemination of recombinant virus and making the transcription of genes, the expression of which must be regulated, more controllable. The ability to deliver adenoviruses via several routes of administration, such as i.m., i.n., intraperitoneally, subcutaneously or orally (this paper ; Prevec et aL, 1989; Baer et al., 1989; Sumner et al., 1988) makes them powerful tools for in vivo expression of foreign genes. As PRV is pathogenic for all species of mammals, except primates, Ad-gp50 can easily be used to study the ability of recombinant Ad5 to be used as a vaccine in a large number of animal species.
